Skip to main page content
Access keys NCBI首页 MyNCBI Homepage Main Content 主要导航
2021年6月10日; 57(6):2100166。
doi: 10.1183/13993003.00166-2021. Print 2021 Jun.

Real world effectiveness of anti-IL-5/5R therapies is independent of co-eligibility for anti-IgE therapy

Affiliations

Real world effectiveness of anti-IL-5/5R therapies is independent of co-eligibility for anti-IgE therapy

安德鲁·P·赫恩(Andrew P Hearn)等。 Eur Respir J
没有抽象可用

Conflict of interest statement

利益冲突:A.P. Hearn没有什么可披露的。利益冲突:O.D。拥抱没有什么可披露的。利益冲突:Z.A.索马尼没有什么可披露的。利益冲突:J. Kavanagh在提交的工作之外报告了Teva的其他(会议的旅行支持)。利益冲突:G。d'Ancona报告了Teva,Gsk,Astrazeneca,Chiesi和Napp的讲座的个人费用,在提交的工作之外。利益冲突:C。Roxas没有什么可披露的。利益冲突:L。Green无话可说。利益冲突:L。Thomson没有什么可披露的。 Conflict of interest: M. Fernandes has nothing to disclose. Conflict of interest: B.D. Kent reports personal fees for lectures from Teva, GSK, AstraZeneca, Chiesi and Napp, outside the submitted work. Conflict of interest: J. Dhariwal reports other (travel support for meetings) from Sanofi, outside the submitted work. Conflict of interest: A.M. Nanzer reports other (travel support for meetings) from Napp, and personal fees for lectures from AstraZeneca, outside the submitted work. Conflict of interest: D.J. Jackson reports personal fees for lectures from Teva, GSK, AstraZeneca, Chiesi and Napp, outside the submitted work.

类似的文章

Publication types

链接 - 更多资源